David Toro Tobon

Endocrinologist and Assistant Professor @MayoClinic, Internist @gtown_medres, MD @UniversidadCES. Views are my own.

[David Toro Tobon @DavidToroT]

Time to challenge the "lifelong" levothyroxine dogma? In Clinical Thyroidology, I review new data: 64% of older adults on ≤50 µg/day successfully stopped at 1 yr. But relaxed TSH targets & long-term unknowns require a careful approach
https://t.co/yIaTjV48bi

@MayoClinicEndo

[David Toro Tobon @DavidToroT]

Current management shifts patients toward invasive procedures for subclinical disease unlikely to cause harm. We need standardized cross-sectional imaging reporting & far more selective follow-up protocols.

[David Toro Tobon @DavidToroT]

Our latest @MayoClinicEndo study uses AI to expose a major driver of thyroid cancer overdiagnosis: incidental findings on routine CT/MRI scans. We built an NLP pipeline to analyze 115,683 patients over 6 years. The data: 🧵

https://t.co/rwQbnFGyTM

@doctorjuanpa

[David Toro Tobon @DavidToroT]

• The diagnostic cascade is massive: an incidental finding led to 46.8x higher odds of biopsy, 55.8x higher odds of total thyroidectomy, and 61.7x higher odds of a cancer diagnosis.
• 88.1% of these detected cancers were small, low-risk papillary carcinomas. 🧵

[David Toro Tobon @DavidToroT]

Our recent commentary examines AI-enhanced molecular diagnostics for thyroid nodules. While combining AI & genetics could improve precision, small cohorts and NIFTP classification remain hurdles to clear before clinical reality
@MayoClinicEndo @TheAACE

https://t.co/GAwabWp58C

[David Toro Tobon @DavidToroT]

Safe AI requires shifting from bedside vigilance to system-level safeguards. This relies on three pillars:

- ​Enterprise accountability and shared risk
- ​Institutionalized stakeholder governance
- ​Continuous automated monitoring.

​Responsibility belongs upstream

[David Toro Tobon @DavidToroT]

The "clinician in the loop" model is a flawed solution for AI oversight. It shifts accountability from developers to doctors, making clinicians the "moral crumple zone" for system failures.

Our new BMJ analysis: 🧵 https://t.co/dfZV6XWfys

@MayoClinicEndo
@doctorjuanpa

[David Toro Tobon @DavidToroT]

We propose an alternative: "AI as adviser". AI should operate in the background to support the therapeutic alliance, rather than mediating it.

[The BMJ @bmj_latest]

Regulators and health systems increasingly rely on human oversight at the point of use as a primary safeguard for AI.

“Clinician in the loop” oversight shifts responsibility for AI safety from developers to doctors
https://t.co/Spb8RwG95J

[Mayo Clinic Endocrinology @MayoClinicEndo]

Build practical diabetes management skills with the Essential Diabetes Care online course—recorded lectures and case studies in a self‑paced 9+ hour online format for providers.

Learn more: https://t.co/LLlcWi60kF

#CME #Diabetes

[Mayo Clinic Endocrinology @MayoClinicEndo]

At @MayoClinicEndo, we are evaluating next-gen therapies targeting the root causes of thyroid autoimmunity. Explore our active clinical trials for Graves' disease and TED here: https://t.co/791vvd12ib

#Endocrinology #ClinicalTrials

[Jairo Noreña MD. @DrJairoNorena]

Colombias in Endocrinology at @TheAACE! Un gusto toparme con @DavidToroT! #AACE2026

[Johnson Thomas, MD, FACE @JohnsonThomasMD]

Practical tips for using AI in clinical practice. Great session by @DavidToroT at #AACE2026

[Mayo Clinic Endocrinology @MayoClinicEndo]

How does the way our bodies process dietary fats affect our weight over time? A new @mayoclinicendo study reveals a key link between meal fatty acid metabolism and long-term weight gain in females

Learn more: https://t.co/BCo9JSjG3n

#WomensHealth #Metabolism #Endocrinology

[David Toro Tobon @DavidToroT]

Overdiagnosis drives unnecessary thyroid biopsies. My commentary explores deploying AI as a "goalkeeper" to double-check flagged nodules. It cut unnecessary FNAs from 68.5% to 9.1%. AI doesn't replace the clinician; it refines our focus.

https://t.co/be8XQtHhJf

@MayoClinicEndo

[David Toro Tobon @DavidToroT]

Thyroid molecular classifiers are likelihood ratios 📊, not magic verdicts 🎱

Our new @JAMAOnc viewpoint explores how to reclaim clinical reasoning and shared decision-making in the era of AI and automated testing

@doctorjuanpa
@vmontori
@MayoClinicEndo https://t.co/I5j5m1gmwr

[David Toro Tobon @DavidToroT]

It was a pleasure to join the great group of the Mexican Society of Endocrinology, discussing management strategies for thyroid eye disease & RAI indications per new ATA guidelines, plus insights on redifferentiation at the International Forum of Thyroid Experts @SMNE_Oficial

[Euro J Endocrinology @EJEndo]

INVITED REVIEW The evolving landscape of Thyroid Eye Disease: present and future by @davidtorot and Marius N Stan @mayoclinicendo

EJE Volume 193, Issue 2, August 2025
👉 https://t.co/tAAywNkksu
ESE Members free via 👉 https://t.co/CESKhK9o08

#endocrinology #thyroid